Article

Improving Access and Support for Cell and Gene Therapies

In 2022, the FDA approved five new cell and gene therapies (CGT)—and approvals for new therapies are only expected to rise in the years to come. But although CGTs are potentially transformative, their effectiveness is undermined by difficulties with patient access and support, high costs, and a complex pathway to treatment. 

Because these cutting-edge therapies require significant patient support, the onus is on sponsor companies, providers, and payers to coordinate care to improve patient access.

Improving connectivity across CGT treatment journey to enable enhanced patient and provider experience

With the launch of the CGT Integration Hub, which is platform-agnostic and powered by Cencora's innovative customer relationship management (CRM) system, we can complete platform integrations with various supply chain partners, including therapy developers and CGT software providers.

For example, Cencora recently completed a platform integration with TrakCel’s cell orchestration platform OCELLOS.

Related resources

White paper

Why an integrated approach ensures smooth entry into the European market
Learn More

Article

HTA Quarterly Spring 2025
Learn More

Article

Early network mapping to guide HTA literature reviews—how do we identify the right evidence efficiently?
Learn More

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.

After reading this playbook, you’ll understand:

  • The patient access problems that are inherent with CGTs  
  • The benefits of data collection and integrated patient support hubs for CGTs 
  • The importance of full buy-in and adoption by nurses, providers, payers, and sponsor companies

cgt

Enter your information to download the playbook

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.